NO933897L - HBV-overflateproteiner med redusert vertskarbohydrat - Google Patents
HBV-overflateproteiner med redusert vertskarbohydratInfo
- Publication number
- NO933897L NO933897L NO933897A NO933897A NO933897L NO 933897 L NO933897 L NO 933897L NO 933897 A NO933897 A NO 933897A NO 933897 A NO933897 A NO 933897A NO 933897 L NO933897 L NO 933897L
- Authority
- NO
- Norway
- Prior art keywords
- hbv
- surface proteins
- carbohydrate
- particles
- captured
- Prior art date
Links
- 102000018697 Membrane Proteins Human genes 0.000 title abstract 4
- 108010052285 Membrane Proteins Proteins 0.000 title abstract 4
- 150000001720 carbohydrates Chemical class 0.000 title abstract 3
- 241000700721 Hepatitis B virus Species 0.000 abstract 6
- 239000002245 particle Substances 0.000 abstract 3
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
Abstract
For å produsere hepatitt B-virus- (HBV)overflateproteiner i form av partikler med betydelig redusert innhold av innfanget karbohydrat ble DNA som koder for HBV-overflateproteinene, ut- trykt i en gjærvert som mangler evnen til å glykosylere proteiner. Disse HBV- overflateproteiner oppviser de antigen- iske seter som genetisk er kodet for av S-domenet av den HBV-virionkappe-åpne avlesningsramme og inneholder betydelig reduserte mengder av innfanget karbo- hydrat sammenlignet med HBsAg-partikler produsert i gjærceller av "villtypen". Disse partikler er anvendelige som en vaksine for både den aktive og passive behandling eller forebyggelse av sykdom og/eller infeksjon forårsaket av HBV eller andre midler serologisk beslektet med HBV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69292491A | 1991-04-29 | 1991-04-29 | |
| PCT/US1992/003472 WO1992019741A1 (en) | 1991-04-29 | 1992-04-27 | Hbv virus surface proteins with reduced host carbohydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO933897D0 NO933897D0 (no) | 1993-10-28 |
| NO933897L true NO933897L (no) | 1993-10-28 |
Family
ID=24782605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO933897A NO933897L (no) | 1991-04-29 | 1993-10-28 | HBV-overflateproteiner med redusert vertskarbohydrat |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5614384A (no) |
| EP (1) | EP0516286B1 (no) |
| JP (1) | JP2637877B2 (no) |
| KR (1) | KR920019373A (no) |
| CN (1) | CN1067680A (no) |
| AT (1) | ATE215987T1 (no) |
| AU (1) | AU650530B2 (no) |
| BG (1) | BG61700B1 (no) |
| CA (1) | CA2067290A1 (no) |
| CZ (1) | CZ282769B6 (no) |
| DE (1) | DE69232541D1 (no) |
| FI (1) | FI934650A7 (no) |
| HU (1) | HUT69149A (no) |
| IE (1) | IE921385A1 (no) |
| IL (1) | IL101651A0 (no) |
| LT (1) | LT3367B (no) |
| MX (1) | MX9201970A (no) |
| NO (1) | NO933897L (no) |
| NZ (1) | NZ242487A (no) |
| PL (1) | PL171485B1 (no) |
| SG (1) | SG55152A1 (no) |
| SK (1) | SK118193A3 (no) |
| WO (1) | WO1992019741A1 (no) |
| YU (1) | YU45492A (no) |
| ZA (1) | ZA923069B (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0533263A3 (en) * | 1991-09-20 | 1994-06-08 | Merck & Co Inc | A multivalent hepatitis b virus vaccine |
| WO1995031558A1 (en) * | 1994-05-16 | 1995-11-23 | Merck & Co., Inc. | Process for producing hbv surface proteins |
| US6300065B1 (en) * | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| AU2212100A (en) * | 1998-12-23 | 2000-07-12 | Merck & Co., Inc. | Improved recombinant hepatitis b surface antigen |
| KR100604994B1 (ko) | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법 |
| CN111187720A (zh) * | 2019-12-27 | 2020-05-22 | 深圳康泰生物制品股份有限公司 | 表达肠道病毒71型抗原的重组汉逊酵母的细胞破碎方法及其在制备手足口病疫苗中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4803164A (en) * | 1981-08-31 | 1989-02-07 | Genentech, Inc. | Preparation of hepatitis b surface antigen in yeast |
| US4707542A (en) * | 1983-08-22 | 1987-11-17 | Merck & Co., Inc. | Immunogenic HbsAg derived from transformed yeast |
| US4816564A (en) * | 1986-01-31 | 1989-03-28 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
| GB8613388D0 (en) * | 1986-06-03 | 1986-07-09 | Delta Biotechnology Ltd | Induction of galactose regulated gene expression in yeast |
| DE3719213C1 (de) * | 1987-06-09 | 1988-05-19 | Daimler Benz Ag | Bodennahe mehrpolige Stromversorgung fuer spurfuehrbare,gummibereifte,elektrisch antreibbare Fahrzeuge |
| US4963483A (en) * | 1987-10-13 | 1990-10-16 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
| US5135854A (en) * | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
| ATE100142T1 (de) * | 1987-10-29 | 1994-01-15 | Zymogenetics Inc | Verfahren zur regulierung der proteinglycosylierung. |
| GB8726953D0 (en) * | 1987-11-18 | 1987-12-23 | Delta Biotechnology Ltd | Yeast expression system |
| NZ229260A (en) * | 1988-06-03 | 1994-02-25 | Merck & Co Inc | Hepatitis b virus, expression cassette for pre-s domain, host cells and |
| EP0414374B1 (en) * | 1989-07-25 | 1997-10-08 | Smithkline Biologicals S.A. | Novel antigens and methods for their preparation |
| CA2022109A1 (en) * | 1989-07-31 | 1991-02-01 | Cheryl A. Schulman | Enhanced expression of heterologous proteins in recombinant hosts in a non-growth media |
| CA2022108A1 (en) * | 1989-07-31 | 1991-02-01 | Cheryl A. Schulman | Enhanced growth and expression of heterologous proteins in recombinant hosts containing mutations in cell wall and/or plasma membrane biosynthesis |
| DE69013471T2 (de) * | 1989-12-05 | 1995-03-30 | Merck & Co Inc | Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe. |
| IL101653A0 (en) * | 1991-04-29 | 1992-12-30 | Merck & Co Inc | Multiple hepatitis b virus surface proteins which form particles |
-
1992
- 1992-04-20 IL IL101651A patent/IL101651A0/xx unknown
- 1992-04-24 NZ NZ24248792A patent/NZ242487A/en unknown
- 1992-04-27 CZ CS932271A patent/CZ282769B6/cs not_active IP Right Cessation
- 1992-04-27 SK SK1181-93A patent/SK118193A3/sk unknown
- 1992-04-27 WO PCT/US1992/003472 patent/WO1992019741A1/en not_active Ceased
- 1992-04-27 CA CA002067290A patent/CA2067290A1/en not_active Abandoned
- 1992-04-27 PL PL92301163A patent/PL171485B1/pl unknown
- 1992-04-27 HU HU9303064A patent/HUT69149A/hu unknown
- 1992-04-28 MX MX9201970A patent/MX9201970A/es unknown
- 1992-04-28 ZA ZA923069A patent/ZA923069B/xx unknown
- 1992-04-28 KR KR1019920007142A patent/KR920019373A/ko not_active Ceased
- 1992-04-28 AU AU15222/92A patent/AU650530B2/en not_active Ceased
- 1992-04-28 YU YU45492A patent/YU45492A/sh unknown
- 1992-04-28 CN CN92104290A patent/CN1067680A/zh active Pending
- 1992-04-29 SG SG1996008131A patent/SG55152A1/en unknown
- 1992-04-29 AT AT92303883T patent/ATE215987T1/de active
- 1992-04-29 EP EP92303883A patent/EP0516286B1/en not_active Expired - Lifetime
- 1992-04-29 DE DE69232541T patent/DE69232541D1/de not_active Expired - Lifetime
- 1992-04-30 JP JP4155566A patent/JP2637877B2/ja not_active Expired - Fee Related
- 1992-07-01 IE IE138592A patent/IE921385A1/en not_active Application Discontinuation
-
1993
- 1993-03-30 LT LTIP462A patent/LT3367B/lt not_active IP Right Cessation
- 1993-10-21 FI FI934650A patent/FI934650A7/fi unknown
- 1993-10-28 NO NO933897A patent/NO933897L/no not_active Application Discontinuation
- 1993-10-29 BG BG98187A patent/BG61700B1/bg unknown
-
1995
- 1995-01-04 US US08/368,287 patent/US5614384A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX9201970A (es) | 1992-11-01 |
| CA2067290A1 (en) | 1992-10-30 |
| CZ227193A3 (en) | 1994-04-13 |
| SG55152A1 (en) | 1998-12-21 |
| SK118193A3 (en) | 1994-03-09 |
| WO1992019741A1 (en) | 1992-11-12 |
| NO933897D0 (no) | 1993-10-28 |
| HUT69149A (en) | 1995-08-28 |
| IE921385A1 (en) | 1992-11-04 |
| CZ282769B6 (cs) | 1997-10-15 |
| ZA923069B (en) | 1992-12-30 |
| CN1067680A (zh) | 1993-01-06 |
| EP0516286A1 (en) | 1992-12-02 |
| HU9303064D0 (en) | 1994-03-28 |
| LT3367B (en) | 1995-08-25 |
| BG61700B1 (bg) | 1998-03-31 |
| PL171485B1 (pl) | 1997-05-30 |
| FI934650A0 (fi) | 1993-10-21 |
| NZ242487A (en) | 1994-07-26 |
| JP2637877B2 (ja) | 1997-08-06 |
| BG98187A (bg) | 1994-06-30 |
| FI934650A7 (fi) | 1993-10-21 |
| AU1522292A (en) | 1993-03-11 |
| LTIP462A (en) | 1994-10-25 |
| DE69232541D1 (de) | 2002-05-16 |
| YU45492A (sh) | 1994-06-10 |
| KR920019373A (ko) | 1992-11-19 |
| JPH06141872A (ja) | 1994-05-24 |
| AU650530B2 (en) | 1994-06-23 |
| EP0516286B1 (en) | 2002-04-10 |
| US5614384A (en) | 1997-03-25 |
| ATE215987T1 (de) | 2002-04-15 |
| IL101651A0 (en) | 1992-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO940660L (no) | HLA - begrensete Hepatit B virus CTL-epitoper | |
| LU91610I2 (fr) | Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé) | |
| DE69942911D1 (de) | Trägerprotein eines polyepitops | |
| WO1993014208A3 (en) | Hepatitis e virus vaccine and method | |
| NO20026044L (no) | Behandling av humant papillomavirus | |
| NO933897L (no) | HBV-overflateproteiner med redusert vertskarbohydrat | |
| CA2115927A1 (en) | Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus | |
| ATE355375T1 (de) | Bakterioferritin aus helicobacter pylori | |
| YU45292A (sh) | Različiti površinski proteini hepatitis b virusa koji obrazuju čestice | |
| DK0586076T3 (da) | Rekombinant adenovirus-vacciner | |
| DK0833903T3 (da) | Multivalent vaccine mod bovint coronavirus og fremgangsmåde til behandling af infektioner forårsaget af bovint coronavirus | |
| JPS5576819A (en) | Attenuated feline infectious peritonitis virus | |
| ATE102650T1 (de) | Mutanten des infektioesen bovinen rhinotracheitisvirus, vakzine die sie enthalten, verfahren zu ihrer herstellung und ihrer verwendung. | |
| CA2116355A1 (en) | Infectious bovine rhinotracheitis virus mutants and vaccines | |
| DZ1550A1 (fr) | Vaccin depourvu de cellules contre le virus de la maladie marek. | |
| EP0288198A3 (en) | Production of peptide | |
| RU93058279A (ru) | Система экспрессии, белок, вакцина, реагент | |
| DK257887A (da) | Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden | |
| JPS5545618A (en) | Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte | |
| Nagano et al. | Virus-inhibiting factor or interferon activity on heterologous animal cells | |
| DE69228063D1 (de) | Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1 | |
| YU30495A (sh) | Postupak za dobijanje hbv površinskih proteina | |
| NO931821L (no) | Hepatitt b vaksinepreparat som omfatter et gallesyresalt | |
| RU97115149A (ru) | Способ вакцинации против вирусного гепатита в | |
| RU96115433A (ru) | Вакцинный штамм вируса кори л-16в, способ его культивирования и живая вакцина для профилактики кори |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |